Pharmaceutical company Redx has on Monday presented the pre-clinical profile of its reversible Bruton’s tyrosine kinase (BTK) inhibitor RXC005 at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California, United States.
Redx has explained that its development candidate RXC005 is a novel, potent and selective, reversible BTK inhibitor with efficacy and equivalent potency against wild-type and cysteine-481 (C481) mutated BTK. Redx’s reversible BTK inhibitor RXC005 aims to target both wild type and C481-mutated BTK.
Redx Said it was progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to begin these trials late 2017.
Dr Neil Murray, CEO of Redx, said: “We’re delighted to have presented the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the ASH 2016 meeting in San Diego.
“RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017.”